ReNeuron's Michael Hunt on 'very significant' exosome therapy data

Published on 19th May 2017

Michael Hunt, CFO for ReNeuron Group Plc (LON:RENE), explains to Proactive their latest research which has been presented at a conference in Canada - highlighting the ability of their exosome therapy candidate to target specific organs of the body.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Pharma & Biotech
Concepta secures two additional myLotus distribution agreements in China

Concepta secures two additional myLotus distribution agreements in China

Published on 16th Oct 2017
Tech
Keywords' Andrew Day shows off shiny new AIM award

Keywords' Andrew Day shows off shiny new AIM award

Published on 16th Oct 2017
Media & Publishing
London Finance Show: Iran and Spain weighing on markets

London Finance Show: Iran and Spain weighing on markets

Published on 16th Oct 2017

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: